Trial shortfalls – including the early termination of patient enrollment and failure to meet an efficacy endpoint – sank Angel Medical Systems Inc.'s implantable cardiac monitor at an FDA Circulatory System Devices advisory panel meeting.
The 12-member panel unanimously voted that the evidence presented by the company for its AngelMed Guardian System did not show...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?